The current financial score of GeneDx Holdings Corp is 7.02. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 114.44M, representing a year-over-year increase of 11.44%, while its net profit experienced a year-over-year increase of 264.12%.
The current valuation score of GeneDx Holdings Corp is 9.16. Its current P/E ratio is -32.03, which is -5304.88% below the recent high of 1666.91 and -302.09% above the recent low of -128.77.
The current earnings forecast score of GeneDx Holdings Corp is 8.67. The average price target is 90.44, with a high of 103.00 and a low of 74.00.
The current price momentum score of GeneDx Holdings Corp is 4.29. Currently, the stock price is trading between the resistance level at 99.86 and the support level at 75.87, making it suitable for range-bound swing trading.
The current institutional shareholding score of GeneDx Holdings Corp is 10.00. The latest institutional shareholding proportion is 113.16%, representing a quarter-over-quarter increase of 1.31%. The largest institutional shareholder is Catherine Wood, holding a total of 1.61M shares, representing 0.72% of shares outstanding, with 37.53% increase in holdings.
The current risk assessment score of GeneDx Holdings Corp is 4.14. The company's beta value is 1.99. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.